All results
16 results for lung cancer
-
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell L
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of…
- Ages
- 18 Years - N/A
- Sexes
- All
-
TAPUR: Testing FDA Approved Drugs That Target Specific Abnormal Tumor Genes in Pts w/Advanced Cancer
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a…
- Ages
- 12 Years - N/A
- Sexes
- All
-
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal…
- Ages
- 18 Years - N/A
- Sexes
- All
-
GSK Nimble
This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to…
- Ages
- 12 Years - N/A
- Sexes
- All
-
NIMBLE
This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to…
- Ages
- 12 Years - N/A
- Sexes
- All
-
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
This phase II ComboMATCH treatment trial evaluates the effectiveness of palbociclib and binimetinib in treating patients with RAS-mutated cancers. Palbociclib…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma
This study builds on the results of several prior studies that we have been involved with to test the hypothesis that Risk-Adapted De-Intensification of…
- Ages
- 18 Years - 99 Years
- Sexes
- All
-
GALACTIC-1
This is a randomized, double-blind, placebo-controlled phase 2b trial in subjects with IPF (idiopathic pulmonary fibrosis) investigating the efficacy and…
- Ages
- 40 Years - N/A
- Sexes
- All
-
PERMET
The PERMET trial will determine whether metformin daily for six months improves six-minute walk performance in individuals with peripheral artery disease…
- Ages
- 18 Years - N/A
- Sexes
- All
-
INBRX101-201
Phase 2 study to compare INBRX-101 to plasma derived A1PI therapy in adults with AATD emphysema This is a Phase 2, Double-Blind, Randomized, Active-Control,…
- Ages
- 18 Years - 80 Years
- Sexes
- All